Jump to content

Biomedical


These projects build on the multi-functionality allowed by 2DMs to demonstrate the advantages of combining e.g. biocompatibility, chemical stability, (bio-) sensing and actuating, and integration with flexible electronic technologies, in addition to versatile surface chemistry (for interface with biology) which allows for continuous health monitoring and built-in pharmacological interventions.

The aim is to offer new technology solutions exploiting the unique properties of 2D materials (2DM) that would reduce cost and increase the efficacy of diagnostics or therapies, or provide new diagnostics or therapies for which there is currently no solution. It would strengthen Europe’s industrial position in, early diagnostics, disease prediction and prevention, disease monitoring and reducing hospitalization time.

Projects

MUNASET


Proteases recently emerged as a promising new class of biomarkers with a broad diagnostic, prognostic and therapeutic potential for different human diseases including neurological and psychiatric diseases, several types of cancer, and immune system disorders. However, there is a lack of tools for real-time activity analysis of disease-related protease biomarkers.

2D-BioPAD


2D-BioPAD is a cost-effective, non-invasive point of care/self-testing tool for the early and accurate prognosis (assistive diagnosis) of Alzheimer's Disease, with special focus on earlier stages such as Subjective or Mild Cognitive Impairment (SCI/MCI).

Latest articles

doctor with graphene solutions MUNASET
MUNASET / Biomedical / Our project

MUNASET: A new Horizon Europe project kicked off


Proteases recently emerged as a promising new class of biomarkers with a broad diagnostic, prognostic and therapeutic potential for different human diseases including neurological and psychiatric diseases, several types of cancer and immune system disorders. However, there is a lack of tools for real-time activity analysis of disease-related protease biomarkers.

By Graphene Flagship / 06 December 2023
Show all news